// App-Quantinova.ai

1227 : Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)

Researchers

Presenter

  • Marianna Sabatino

Principal Investigators

  • N/A

Medical Centers

  • Kite Pharma, Santa Monica, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Adenomatous Polyposis Coli

  • Breakpoint Cluster Region

Drug/Treatment

  • Interleukin

  • Axicabtagene ciloleucel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved